Clinicopathological Criteria for Multicentricity of Hepatocellular Carcinoma and Risk Factors for Such Carcinogenesis

Shoji Kubo,1,5 Shuhei Nishiguchi,2 Kazuhiro Hirohashi,1 Taichi Shuto,1 Tetsuo Kuroki,2 Shin Minamitani,2 Takatsugu Yamamoto,3 Kenichi Wakasa4 and Hiroaki Kinoshita1

1Second Department of Surgery, 2Third Department of Internal Medicine, 3Second Department of Pathology, Osaka City University Medical School and 4Department of Pathology, Osaka City University Hospital, 1-5-7 Asahimachi, Abeno-ku, Osaka 545

Multicentric occurrence is an important characteristic of hepatocellular carcinoma. We evaluated clinicopathological criteria for multicentric hepatocellular carcinoma and identified risk factors for such carcinogenesis. Subjects were 251 consecutive patients undergoing liver resection for hepatocellular carcinoma. One kind of multicentric hepatocellular carcinoma had at least one tumor consisting of well-differentiated hepatocellular carcinoma, together with moderately or poorly differentiated hepatocellular carcinoma located in a separate region. The other kind had an area of well-differentiated component around hepatocellular carcinoma with less differentiation in all occurrences. The outcome of patients with tumors classified in this way was studied. Univariate and multivariate analyses were done to identify risk factors for multicentric hepatocellular carcinoma. The cumulative survival rate was significantly higher in patients with multicentric hepatocellular carcinoma than in patients with hepatocellular carcinoma associated with intrahepatic metastasis. Analysis by Cox's proportional hazard model showed that multicentricity was not a factor in the outcome. The risk of multicentric occurrence increases with progression of chronic liver disease. Univariate analysis showed hepatitis C virus marker and hepatitis B core antibody to be risk factors. By multivariate analysis, the odds ratio for multicentric occurrence in patients infected with hepatitis C virus and with serum hepatitis B virus core antibody compared with patients without either hepatitis C virus or hepatitis B virus was 10.86. This ratio in patients with hepatitis C virus alone was 4.30. These criteria for multicentric hepatocellular carcinoma seem to be clinically useful. Hepatitis C virus infection with or without former infection by hepatitis B virus is a strong risk factor for multicentric hepatocarcinogenesis.

Key words: Hepatocellular carcinoma — Hepatitis B virus — Hepatitis C virus — Multicentricity — Liver cirrhosis

Recent studies in molecular biology have shown that some hepatocellular carcinomas (HCCs) are multicentric in origin.1–5) It is important to know for individual patients whether multiple tumors in the liver are multicentric or metastases originated from a main tumor to decide the most appropriate treatment, because the results of treatment for single (unicentric) HCCs, multicentric HCCs, and HCCs with intrahepatic metastasis differ.6–8) Hepatitis C virus (HCV) and hepatitis B virus (HBV) are risk factors for HCC.9) In Japan10–12) and Europe,13) the incidence of HCC is higher in patients with HCV than in those with HBV. The difference in the incidence of HCC in patients with HCV or HBV affects decisions about treatment, because these viruses are factors in the outcome after surgery.14,15) HCV-related HCCs tend to be multifocal7,8) but no large-scale studies on the incidence of and risk factors for multicentric occurrence of HCC have been reported.

We retrospectively evaluated criteria for identification of multicentric HCCs from clinicopathological findings, examined the clinical differences among patients with single HCC, multicentric HCCs, and HCCs with intrahepatic metastasis, and investigated risk factors in multicentric carcinogenesis, especially the roles of HCV and HBV.

PATIENTS AND METHODS

Patients Subjects were all 251 patients who had undergone liver resection for HCC at our hospital during the past 6 years up to June 1996. Before surgery, patients underwent sonography, computed tomography, angiography, and (for most patients) magnetic resonance imaging. Intraoperative sonography also was done in all patients, and when a nodule(s) not detected earlier was found, it was biopsied. If the nodule was malignant or premalignant, it was resected, treated with microwaves, or injected with ethanol. This study was conducted in accordance with the Helsinki Declaration and the guidelines of the ethics committee of our institution. Informed consent was obtained from each patient.

Virus markers Serum samples obtained before surgery from all patients were assayed for HCV and HBV. Serum
was examined for hepatitis B surface antigen (HBsAg) with an enzyme immunoassay (International Reagents Corp., Kobe), and for hepatitis B core antibody (HBcAb) with a radioimmunoassay (Dinabot, Tokyo). Samples were examined for HCVAb by second- or third-generation enzyme-linked immunosorbent assay (Ortho Diagnostic Systems, Tokyo). Serum was examined for HCV RNA by means of the polymerase chain reaction with reverse transcription (RT-PCR) and with primers derived from a conserved 5'-untranslated region of the viral genome. Serum HBV DNA was assayed by nested PCR as reported previously. Pathological examination Resected specimens were cut into serial slices 5 mm thick and fixed in 10% formalin. Biopsy specimens were also fixed in 10% formalin. Sections from trimmed paraffin blocks containing at least one nodule were stained with hematoxylin and eosin. The number of sections examined was at least 10 for each patient and the maximum number was 302. A pathologic diagnosis was made based on the General Rules for the Clinical and Pathological Study of Primary Liver Cancer in Japan, with some modifications. Well-differentiated HCC had high cell density, a high nucleus/cytoplasm ratio, strong cytoplasmic eosinophilia, and an irregular pattern with thin trabeculae; occasionally, the pattern was pseudoglandular. There was replacement growth at the boundary between the tumor and healthy tissue. Multicentric occurrence of HCC was classified into two categories: pattern 1, at least one tumor consisting of well-differentiated HCC grew in a replacement growth pattern, with hepatic structures maintained, and with moderately or poorly differentiated HCC elsewhere (near or far); a tumor embolus might be found in the portal vein of the main tumor. In the other kind (pattern 2), an area of well-differentiated HCC surrounded an area of HCC showing less differentiation in all occurrences. The validity of these criteria is suggested by metastases not being detected in other studies from well-differentiated HCC or from HCC of Edmondson-Steiner grade I, and also by evidence that carcinogenesis occurs in steps in Japan, with some modifications. In one kind of occurrence, any occurrence of HCC of Edmondson-Steiner grade I, and also by evidence that carcinogenesis occurs in steps in Japan, with some modifications. In one kind of occurrence, any occurrence of HCC of Edmondson-Steiner grade I, and also by evidence that carcinogenesis occurs in steps in Japan, with some modifications.

Risk factors for multicentric HCCs We evaluated risk factors and calculated the relative risk of a number of variables for multicentric HCCs by univariate and multivariate analysis. The variables were selected for their potential relationship to multicentric occurrence as suggested by studies of the development of HCC in patients with chronic liver disease or by our own clinical experience. The variables chosen were the kind of virus(es) causing the infection, age, sex, history of heavy drinking [intake of at least 86 g of ethanol daily for at least 10 years], history of blood transfusion, presence of liver cirrhosis, activity of hepatitis, and results of laboratory tests for α-fetoprotein concentration, indocyanine green retention rate at 15 min (ICGR15), aspartate aminotransferase (AST), alanine aminotransferase (ALT) activity, total bilirubin concentration, platelet count, and albumin concentration.

Statistics Statistical analysis was done with SAS 6.11 (SAS Institute, Inc.). Analysis of variance followed by the Tukey method was used to compare the results of laboratory tests. If the results did not have a normal distribution, the analysis was done after logarithmic transformation. The χ² test followed by Bonferroni’s method was used to compare categorical data among groups. Survival curves after surgery were calculated by the Kaplan-Meier method and the significance of differences was evaluated by the log-rank test. Cox’s proportional hazards model was also used. Differences with P<0.05 were considered to be statistically significant. The odds ratio was used to estimate relative risk for multicentric HCC. For univariate analysis, logistic regression analysis was used. For multivariate analysis, multiple logistic regression analysis with a step-wise procedure was used.

RESULTS

Profile of the subjects The profiles of the patients are summarized in Table I. Patients who received blood transfusions after 1989 when the screening of donated blood for HBcAb and HCVAb began are not listed here as having had transfusions, because the chance of infection with HCV and HBV became negligible. Twenty-six of the 38 patients with serum HBsAg had a family history of liver disease and 24 of the 123 patients with serum HBcAb, but not HBsAg had such a history. In one patient without serum HCVAb, HCV RNA was detected by RT-PCR. In 8 of the 182 patients with serum HCVAb, HCV was not detected by RT-PCR. The 183 patients in whom HCV was detected by RT-PCR or with serum HCVAb were assumed to be infected with HCV. Serum HBV DNA was not detected by PCR in any patient whose serum had neither HBsAg nor HBcAb.

Of the 251 patients, 95 had multiple HCCs. Of the 95 patients, 28 patients had multicentric HCCs alone, 58
Multicentric Hepatocellular Carcinoma

Patients had HCCs with intrahepatic metastasis but without multicentric HCCs, and 9 patients had multicentric HCCs and intrahepatic metastasis; 156 patients had single HCC. Therefore, 37 patients had multicentric HCCs with or without intrahepatic metastasis. HCCs in 35 of the 37 patients were judged as multicentric HCCs by the criteria pattern 1 and HCCs in 2 other patients were judged as such HCCs by the criteria pattern 2.

Appropriateness of the clinicopathological criteria for multicentricity of HCCs

Curves of survival rates after surgery are shown in Fig. 1. The rate was significantly different among groups ($P < 0.001$). The rate was higher in patients with multicentric HCCs than in patients with intrahepatic metastasis but without multicentric HCCs ($P = 0.005$). The rate was not different between patients with multicentric HCCs and with single HCCs. Analysis by Cox’s proportional hazards model showed that intrahepatic metastasis was a factor in the outcome ($P < 0.0001$); the relative risk was 3.94 (CI, 2.13–7.29). Multicentric occurrence was not a risk factor ($P = 0.435$). Therefore, the clinicopathological criteria that we describe for multicentric occurrence of HCC appear to be of practical use.

Clinical characteristics of multicentric HCC

The prevalence of HCV was significantly higher in the patients with multicentric HCCs alone than in patients with single HCC ($P < 0.001$) or with intrahepatic metastasis ($P < 0.005$; Table I). The prevalence of HBcAb was significantly different in each of the groups overall by the $\chi^2$ test ($P < 0.05$), but no significant difference was found between groups by Bonferroni’s method. AST activity was significantly higher in patients with multicentric HCCs than in patients with single HCC ($P < 0.05$). ALT activity was significantly higher in patients with multicentric HCC alone than in patients with single HCC ($P < 0.05$) or with intrahepatic metastasis ($P < 0.05$).

### Table I. Profile of the Patients

|                  | Single HCC $n=156$ | Multicentric HCC alone $n=28$ | HCC with intrahepatic metastasis $n=58$ | Multicentric HCC with intrahepatic metastasis $n=9$ |
|------------------|--------------------|-------------------------------|--------------------------------------|-----------------------------------------------|
| Age, years (mean±SD) | 59±8              | 63±4                          | 61±10                                | 63±4                                          |
| Sex ratio (M:F)   | 122:34            | 22:6                          | 48:10                                | 9:0                                           |
| Heavy drinker$^a$| 45                | 6                             | 6                                   | 5                                             |
| History of blood transfusion$^a$ | 29 | 11                           | 12                                   | 2                                             |
| Family history of liver disease$^a$ | 42 | 5                            | 15                                   | 2                                             |
| Viral markers$^a$ |                   |                               |                                      |                                               |
| HCV/Ab or RNA     | 108               | 28                            | 40                                   | 8                                             |
| HBsAb             | 28                | 0                             | 9                                    | 1                                             |
| HBcAb             | 69                | 20                            | 25                                   | 7                                             |
| $\alpha$-Fetoprotein (≥20 ng/ml)$^a$ | 76 | 12                           | 34                                   | 4                                             |
| ICGR$_{15}$ (%)   | 17.3 (8.5, 31.3)  | 20.8 (9.9, 31.2)              | 15.3 (6.2, 26.4)                     | 18.4 (8.5, 23.8)                              |
| AST (IU/liter)$^b$| 54 (31, 93)       | 65 (49, 123)                  | 67 (30, 137)                        | 62 (26, 154)                                  |
| ALT (IU/liter)$^b$| 61 (27, 125)      | 98 (41, 124)                  | 50 (24, 121)                        | 69 (27, 137)                                  |
| Total bilirubin (mg/dl)$^b$ | 0.8 | 0.9 (0.6, 1.4) | 0.9 (0.5, 1.5) | 0.9 (0.5, 1.8) |
| Albumin (g/dl)$^b$ | 3.7 (3.2, 4.2)    | 3.5 (3.1, 4.0)                | 3.6 (3.1, 4.1)                      | 3.8 (2.8, 4.2)                                |
| Platelet count ($\times10^4$/mm$^3$)$^b$ | 13.4 | 10.3 (7.3, 18.3) | 14.3 (8.3, 26.1) | 12.1 (4.8, 33.4) |
| Cirrhosis$^c$    | 105              | 24                            | 42                                   | 7                                             |

$^a$ Numbers of patients.
$^b$ Median with 10th and 90th percentiles.
$^c$ $P < 0.001$ compared with patients with single HCC and $P < 0.005$ compared with patients with intrahepatic metastasis.
$^d$ $P < 0.05$ compared with patients with single HCC.
$^e$ $P < 0.05$ compared with patients with single HCC or with intrahepatic metastasis.

Risk factors for multicentric HCCs

Table II shows the odds ratios of possible risk factors for multicentric HCC calculated by univariate analysis. By univariate analysis, HCV, HBcAb, history of blood transfusion, ICGR$_{15}$, ALT activity, total bilirubin, and platelet count were significant factors. The odds ratios for the categories of HCV, HBcAb, male sex, history of blood transfusion, and liver cirrhosis were each more than 2.0. The odds ratios for ICGR$_{15}$, AST, ALT, and total bilirubin were more than 1.0 and the odds ratios for the platelet count and albumin were less than 1.0, indicating that the risk of multicentric carcinogenesis increases as ICGR$_{15}$, AST and ALT activities, and the total bilirubin level increase and as the platelet count and the albumin level decrease. Adenomatous hyperplasia was not a risk factor (data not shown).
III shows adjusted odds ratios of selected variables calculated by multivariate analysis. The adjusted odds ratio of HCV was 4.455 and the ratio of HBcAb was 2.809. The risk increased as the total bilirubin level increased. These results indicate that the state of infection by hepatitis viruses was important. Therefore, odds ratios of various viral states were studied (Table IV). Compared with the ratio for patients without HCV infection and without serum HBsAg or HBcAb, the ratio in patients infected with HCV and with serum HBcAb was 10.86; the ratio in patients infected with HCV alone was 4.30. The odds ratio for the patients with serum HBsAg and HBcAb was 0.42. The results suggest that some interaction between current HCV infection and prior infection with HBV is involved in the development of multicentric HCCs.

DISCUSSION

Whether tumors in a particular patient are multicentric in origin can be found by examination of integrated HBV DNA3,9) in HBV-related HCC, the pattern of loss of heterozygosity on chromosome 16,4) and the mutation pattern of the p53 gene.33) HCV is unlikely to be integrated into the genome,26) and clonal analysis cannot be used to investigate the multicentricity of tumors in patients infected with HCV. Examination of heterozygosity on chromosome 16 and of mutation of the p53 gene is not possible routinely. For clinical use, a simpler method to decide whether HCC is probably multicentric is needed. In Japan, various clinicopathological criteria described above (see “Pathologic examination”) are currently being used.

Table II. Odds Ratios of Possible Risk Factors for Multicentric HCC, Calculated by Univariate Analysis

| Variables | Odds ratio | 95% CI |
|-----------|------------|--------|
| Without HCVAb or RNA | 1.000 | |
| With HCVAb or RNA | 7.804 | 1.823–33.409 |
| Without HBsAg or HBCAb | 1.000 | |
| Without HBsAg but with HBcAb | 2.653 | 1.141–6.165 |
| With HBsAg and HBCAb | 0.191 | 0.023–1.581 |
| Female | 1.000 | |
| Male | 2.950 | 0.866–10.10 |
| Not heavy drinker | 1.000 | |
| Heavy drinkera | 1.061 | 0.494–2.280 |
| Without history of blood transfusion | 1.000 | |
| Without liver cirrhosis | 2.355 | 0.938–5.913 |
| Without active hepatitis | 1.000 | |
| With active hepatitis | 1.316 | 0.654–2.651 |
| Age (per year) | 1.026 | 0.980–1.075 |
| α-Fetoprotein (per 1 ng/ml) | 1.000 | 1.000 |
| ICGR15 (per percentage point) | 1.040 | 1.002–1.079 |
| Aspartate aminotransferase | 1.005 | 0.998–1.013 |
| (per 1 IU/liter) | | |
| Alanine aminotransferase | 1.011 | 1.003–1.020 |
| (per 1 IU/liter) | | |
| Total bilirubin (per 0.1 mg/dl) | 1.329 | 1.026–1.759 |
| Platelet count (per 10⁷/mm³) | 0.930 | 0.869–0.995 |
| Albumin (per 1 g/dl) | 0.580 | 0.236–1.425 |

a) Heavy drinking was as defined by the Liver Cancer Study Group of Japan28) (intake of at least 86 g of ethanol daily for at least 10 years).
b) The 15-min indocyanine green retention rate.

Table III. Adjusted Odds Ratios of Possible Risk Factors for Multicentric HCC, Calculated by Multivariate Analysis

| Variables | Adjusted odds ratio | 95% CI |
|-----------|---------------------|--------|
| Without HCVAb or RNA | 1.000 | |
| With HCVAb or RNA | 4.455 | 0.928–21.381 |
| Without HBsAg or HBCAb | 1.000 | |
| Without HBsAg but with HBcAb | 2.809 | 1.169–6.752 |
| With HBsAg and HBCAb | 0.447 | 0.047–4.243 |
| Total bilirubin (per 0.1 mg/dl) | 1.396 | 1.043–1.996 |

The stepwise procedure was done with variables other than viral markers.
in decisions about treatment. The significant difference in the outcome of patients with multicentric HCCs and patients with HCCs with intrahepatic metastasis, and the lack of a significant difference in the outcome of patients with multicentric HCCs and patients with single HCC were confirmed again in the results reported here. In addition, the cumulative survival rate in patients with intrahepatic metastasis reported previously seems to be worse than the rates in this study. The findings indicate that the criteria used here to distinguish between multicentric HCC and metastasis originating from a main tumor are of clinical value, although there is a possibility that all tumors consisting of moderately or poorly differentiated HCC will be taken to be metastatic.

Many risk factors for the development of HCC have been reported: age, male sex, alcohol abuse, history of blood transfusion, liver cirrhosis, and infection by a hepatitis virus. In our study, HCV, HBcAb, and history of blood transfusion were significant risk factors. The odds ratios for the viral state, male sex, history of blood transfusion, and liver cirrhosis were all more than 2.0. We found an odds ratio for liver cirrhosis of 2.355 and one for active hepatitis of 1.316 by univariate analysis. We also found that AST and ALT activities were significantly higher in patients with multicentric HCC alone than in patients with single HCC and that the risk of multicentric carcinogenesis increased as ICGR15, AST, ALT, and total bilirubin increased and as the platelet count and albumin level decreased. These results indicate that the potential of multicentric carcinogenesis increased with the progression of chronic liver disease and that continuous hepatitis is responsible for such carcinogenesis.

In this study, the prevalence of HCV was significantly higher in patients with multicentric HCCs alone than in patients with single HCC or in patients with intrahepatic metastasis. HCV seems to be a stronger risk factor than HBV in multicentric HCCs. The difference may be related to the higher incidence of HCC development in patients with HCV (about 7% per year in Japan) than in patients with HBV. The high odds ratio for having HBcAb with or without HCV suggests that HBV infection in the past or present may be important for HCC development, especially in the presence of HCV. The mechanism of the interaction, if any, of HCV and HBV during multicentric carcinogenesis is unknown. Some investigators have found that co-infection of HCV and HBV has a synergistic effect on HCC development. Recent analysis of HBV DNA sequences showed that the HBx gene is sometimes detected in HCC and noncancerous tissues in patients without HBsAg. The HBV DNA is integrated into the cellular genome, after which rearrangements of the cellular DNA, insertional mutagenesis, production of truncated HBV proteins such as preS2/S and X proteins, activation of cellular proto-oncogenes, and inhibition of the function of p53 may lead to carcinogenesis. In one possible mechanism, genetic changes or carcinogenesis caused by integration of HBV gene could be worsened in the presence of the continuous hepatitis caused by HCV.

The odds ratio for having both HCV and HBsAg was 1.80, but because there were only 10 such patients, we cannot interpret this result. On the other hand, the odds ratio for having HBsAg alone was low. The mean age at detection of HCC is lower for patients with HBsAg alone than for patients with HCV infection. The likelihood of multicentric carcinogenesis is low in patients with HBsAg because the HCC often develops before cirrhosis.

The results in this study indicate that the clinicopathological criteria for multicentric HCC are of practical value and that HCV infection and a combination of current HCV infection and prior infection of HBV (perhaps with an integrated HBV gene or genes) are strong risk factors for multicentric HCCs. When treatment for HCC is being selected, the viral state of the patient must be taken into account.

### Table IV. Odds Ratios of Various Patterns of Viral Infection

| Viral state | No. of patients | No. of patients with multicentric tumors (%) | Odds ratio | 95% CI |
|------------|----------------|--------------------------------------------|------------|-------|
| + – –      | 65             | 7 (11)                                     | 4.30       | 0.91–20.26 |
| + – +      | 108            | 28 (26)                                    | 10.86      | 0.99–119.66 |
| + + +      | 10             | 0 (0)                                      | 1.80       | 0.04–78.39 |
| – – –      | 15             | 1 (7)                                      | 1.00       | 1.00   |
| – – +      | 15             | 0 (0)                                      | 2.53       | 1.08–5.91 |
| – + +      | 38             | 1 (3)                                      | 0.42       | 0.05–3.87 |
| Total      | 251            | 37a)                                       |            |       |

a) Nine of the 37 patients also had HCCs other than multicentric HCCs.
consideration. Different states carry different risks of multicentric HCCs, even after resection of HCC.

ACKNOWLEDGMENTS

We thank Professor M. Sakurai for his advice in the pathological examinations; Mr. K. Nukui for statistical analysis; and Professor S. Fukushima and Ms. C. Latta for reading the manuscript. This work was supported in part by grants from the Ministry of Education, Science, Sports, and Culture and Ministry of Health and Welfare, Japan.

(Received December 5, 1997/Revised January 21, 1998/Accepted January 23, 1998)

REFERENCES

1) Tsuda, H., Hirohashi, S., Shimosato, Y., Terada, M. and Hasegawa, H. Clonal origin of atypical adenomatous hyperplasia of the liver and clonal identity with hepatocellular carcinoma. Gastroenterology, 95, 1664–1666 (1988).

2) Sakamoto, M., Hirohashi, S., Tsuda, H., Shimosato, Y., Makuchui, M. and Hosoda, Y. Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am. J. Surg. Pathol., 13, 1064–1067 (1989).

3) Hsu, H. C., Chiu, T. J., Chen, J. Y., Lee, C. S., Lee, P. H. and Peng, S. Y. Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules. Hepatology, 13, 923–928 (1991).

4) Tsuda, H., Oda, T., Sakamoto, M. and Hirohashi, S. Different pattern of chromosomal allelic loss in multiple hepatocellular carcinomas as evidence of their multifocal origin. Cancer Res., 52, 1504–1509 (1992).

5) Okuda, K., Tanaka, M., Nakayama, K., Saito, H., Tanikawa, K., Nakashima, O. and Kojiro, M. Clinicopathologic comparison between resected hepatocellular carcinoma (HCC) and recurrent tumors: a special reference to multicentric carcinogenesis of HCC. Inter. Hepatol. Commun., 1, 65–71 (1993).

6) Takenaka, K., Adachi, E., Nishizaki, T., Hiroshige, K., Ikeda, T., Tsuneyoshi, M. and Sugimachi, K. Possible multicentric occurrence of hepatocellular carcinoma: a clinicopathological study. Hepatology, 19, 889–894 (1994).

7) Miyagawa, S., Kawasaki, S. and Makuchui, M. Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C. Hepatology, 24, 307–310 (1996).

8) Nakano, S., Haratake, J., Okamoto, K. and Takeda, S. Investigation of resected multinodular hepatocellular carcinoma: assessment of unicentric or multicentric genesis from histological and prognostic viewpoint. Am. J. Gastroenterol., 89, 189–193 (1994).

9) Sherlock, S. Viruses and hepatocellular carcinoma. Gut, 35, 828–832 (1994).

10) Ikeda, K., Saitoh, S., Koida, I., Arase, Y., Tsubota, A., Chayama, K., Kumada, H. and Kawanishi, M. A multivariate analysis of risk factors for hepatocellular carcinoma: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology, 18, 47–53 (1993).

11) Takano, S., Yokosuka, O., Imazeki, F., Tagawa, M. and Omata, M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology, 21, 650–655 (1995).

12) Kubo, S., Nishiguchi, S., Hirohashi, K., Tanaka, H., Tsukamoto, T., Hamba, H., Shuto, T., Okuda, T., Tamori, A., Kuroki, T. and Kinoshita, H. High prevalence of hepatitis B and C viruses in patients with hepatocellular carcinoma in Japan. Hepato-Gastroenterology, in press.

13) Ganne-Carrié, N., Chastang, C., Chapel, F., Munz, C., Patéron, D., Sibony, M., Dény, P., Trinchet, J.-C., Callard, P., Guettier, C. and Beaumard, M. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology, 23, 1112–1118 (1996).

14) Takenaka, K., Yamamoto, K., Taketomi, A., Itasaka, H., Adachi, E., Shirabe, K., Nishizaki, T., Yanaga, K. and Sugimachi, K. A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. Hepatology, 22, 20–24 (1995).

15) Shuto, T., Hirohashi, K., Kubo, S., Tsukamoto, T., Yamamoto, T., Wakasa, K. and Kinoshita, H. Differences of resected hepatocellular carcinoma with hepatitis B or C virus. Hepato-Gastroenterology, in press.

16) Nishiguchi, S., Kuroki, T., Nakatani, S., Morimoto, H., Takeda, T., Nakajima, S., Shiomi, S., Seki, S., Kobayashi, K. and Otani, S. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet, 346, 1051–1055 (1995).

17) Minamimata, S., Nishiguchi, S., Kuroki, T., Otani, S. and Monna, T. Detection by ligase chain reaction of precore mutant of hepatitis B virus. Hepatology, 25, 216–222 (1997).

18) Liver Cancer Study Group of Japan. “The General Rules for the Clinical and Pathological Study of Primary Liver Cancer,” 3rd Ed., pp. 1–76 (1992). Kanehara, Tokyo (in Japanese).

19) Kanai, T., Hirohashi, S., Upton, M. P., Noguchi, M., Kishi, K., Makuchui, M., Yamasaki, S., Hasegawa, H., Takayasu, K., Moriyama, N. and Shimosato, Y. Pathology of small hepatocellular carcinoma: a proposal for a new gross classification. Cancer, 60, 810–819 (1987).

20) Kondo, F., Wada, K., Nagato, Y., Nakajima, T., Kondo, Y., Hirooka, N., Ebara, M., Ohno, M. and Okuda, K. Biopsy diagnosis of well-differentiated hepatocellular carcinoma
Multicentric Hepatocellular Carcinoma

based on new morphologic criteria. *Hepatology*, 9, 751–755 (1989).

21) Sakamoto, M., Hirohashi, S. and Shimosato, Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. *Hum. Pathol.*, 22, 172–178 (1991).

22) Sato, M., Watanabe, Y., Lee, T., Kito, K., Kimura, S., Itoh, Y., Akamatsu, K. and Ueda, N. Well-differentiated hepatocellular carcinoma: clinicopathological features and results of hepatic resection. *Am. J. Gastroenterol.*, 90, 112–116 (1995).

23) Edmondson, H. A. and Steiner, P. E. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. *Cancer*, 7, 462–503 (1954).

24) Kenmochi, K., Sugihara, S. and Kojiro, M. Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in small HCC. *Liver*, 7, 18–26 (1987).

25) Arakawa, M., Kage, M., Sugihara, S., Nakashima, T., Suenaga, M. and Okuda, K. Emergence of malignant lesions within an adenomatous hyperplastic nodule in a cirrhotic liver: observations in five cases. *Gastroenterology*, 91, 198–208 (1986).

26) Sakurai, M., Kasaka, K., Monden, M., Yamada, T., Kuroda, C., Marukawa, T. and Okamura, J. Hepatocellular carcinoma in adenomatous hyperplasia of the liver. *Cancer Chemother. Pharmacol.*, 23 (Suppl.), S110–S113 (1989).

27) Takayama, T., Makuchii, T., Hirohashi, S., Sakamoto, M., Okazaki, N., Takayasu, K., Kosuge, T., Motoo, Y., Yamazaki, S. and Hasegawa, H. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. *Lancet*, 336, 1150–1153 (1990).

28) Sugihara, S., Nakashima, O., Kojiro, M., Majima, Y., Tanaka, M. and Tanikawa, K. The morphologic transition in hepatocellular carcinoma: a comparison of the individual histologic features disclosed by ultrasound-guided fine-needle biopsy with those of autopsy. *Cancer*, 79, 1488–1492 (1992).

29) Liver Cancer Study Group of Japan. Primary liver cancer in Japan: clinicopathologic features and results of surgical treatment. *Ann. Surg.*, 211, 277–287 (1990).

30) Desmet, V., Gerber, M., Hoofnagle, J. H., Manns, M. and Scheuer, P. J. Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology*, 19, 1513–1520 (1994).

31) Oda, T., Tsuda, H., Scarpa, A., Sakamoto, M. and Hirohashi, S. Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. *Cancer Res.*, 52, 3674–3678 (1992).

32) Yamanaka, N., Okamoto, E., Toyosaka, A., Mitunobu, M., Fujihara, S., Kato, T., Fujimoto, J., Oriyama, T., Furukawa, K. and Kawamura, E. Prognostic factors after hepatectomy for hepatocellular carcinoma: a univariate and multivariate analysis. *Cancer*, 65, 1104–1110 (1990).

33) Kosuge, T., Makuchi, M., Takayama, T., Yamamoto, J., Shimada, K. and Yamasaki, S. Long-term results after resection of hepatocellular carcinoma: experience of 480 cases. *Hepato-Gastroenterology*, 40, 328–332 (1993).

34) Di Carlo, V., Ferrari, G., Castoldi, R., Nadalin, S., Marenghi, C., Molteni, B., Taccagni, G. and Castrucci, M. Surgical treatment and prognostic variables of hepatocellular carcinoma in 122 cirrhotics. *Hepato-Gastroenterology*, 42, 222–229 (1995).

35) Yu, M. C., Tong, M. J., Coursaget, P., Ross, R. K., Govindarajan, S. and Henderson, B. E. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. *J. Natl. Cancer Inst.*, 82, 1038–1041 (1990).

36) Kaklamani, E., Trichopoulos, D., Tzonou, A., Zavitsanos, X., Koumantaki, Y., Hatziakis, A., Hsieh, C. C. and Hatziyannis, S. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. *JAMA*, 265, 1974–1976 (1991).

37) Kubo, S., Nishiguchi, S., Tamori, A., Hirohashi, K., Kinoshita, H. and Kuroki, T. Development of hepatocellular carcinoma in patients with HCV infection, with or without past HBV infection, and relationship to age at the time of transfusion. *Vox Sang.*, 74, 129 (1998).

38) Bréchot, C., Degos, F., Lugassy, C., Thiens, V., Zafrani, S., Franco, D., Bismuth, H., Trépo, C., Benhamou, J.-P., Wands, J., Isselbacher, K., Tiollais, P. and Berthelot, P. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. *N. Engl. J. Med.*, 312, 270–276 (1985).

39) Paterlini, P., Gerken, G., Nakajima, E., Terre, S., D’Errico, A., Grigioni, W., Nalpas, B., Franco, D., Wands, J., Kew, M., Pisi, E., Tiollais, P. and Bréchot, C. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. *N. Engl. J. Med.*, 323, 80–85 (1990).

40) Lai, M. Y., Chen, P. J., Yang, P. M., Sheu, J. C., Sung, J. L. and Chen, D. S. Identification and characterization of intrahepatic hepatitis B virus DNA in HBsAg-seronegative patients with chronic liver disease and hepatocellular carcinoma in Taiwan. *Hepatology*, 12, 575–581 (1990).

41) Urashima, T., Saigo, K., Kobayashi, S., Imaseki, H., Matsubara, H., Koide, Y., Asano, T., Kondo, Y., Koike, K. and Isomo, K. Identification of hepatitis B virus integration in hepatitis C virus-infected hepatocellular carcinoma tissues. *J. Hepatol.*, 26, 771–778 (1997).

42) Hino, O., Tabata, S. and Hotta, Y. Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. *Proc. Natl. Acad. Sci. USA*, 88, 9248–9252 (1991).

43) Pasquinelli, C., Garreau, F., Bouguerel, L., Cariani, E., Grezeschik, K. H., Thiers, V., Croissant, O., Hadchouel, M., Tiollais, P. and Bréchot, C. Rearrangement of a common cellular DNA domain on chromosome 4 in human primary liver tumors. *J. Virol.*, 62, 629–632 (1988).

44) Wang, J., Chenivesse, X., Henglein, B. and Bréchot, C. Hepatitis B virus integration in a cyclin A gene in a hepa-
tocellular carcinoma. *Nature*, 343, 555–557 (1990).
45) Dejean, A., Bougueleret, L., Grzeschik, K.-H. and Tiollais, P. Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. *Nature*, 322, 70–72 (1986).
46) Graef, E., Caselmann, W. H., Wells, J. and Koshy, R. Insertional activation of mevalonate kinase by hepatitis B virus DNA in a human hepatoma cell line. *Oncogene*, 9, 81–87 (1994).
47) Kim, C.-M., Koike, K., Saito, I., Miyamura, T. and Jay, G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. *Nature*, 351, 317–320 (1991).
48) Koike, K. and Terada, S. Biochemistry and functions of hepatitis B virus X protein. *Intervirology*, 38, 89–99 (1995).
49) Shiratori, Y., Shiina, S., Imamura, M., Kato, N., Kanai, F., Okudaira, T., Teratani, T., Tohgo, G., Toda, N., Ohashi, M., Ogura, K., Niwa, Y., Kawabe, T. and Omata, M. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-[sic] viral infection in Japan. *Hepatology*, 22, 1027–1033 (1995).